Detalhe da pesquisa
1.
Author Correction: 'Stealth' corporate innovation: an emerging threat for therapeutic drug development.
Nat Immunol
; 20(11): 1556, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31605100
2.
Novel mechanisms and functions of complement.
Nat Immunol
; 18(12): 1288-1298, 2017 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-29144501
3.
'Stealth' corporate innovation: an emerging threat for therapeutic drug development.
Nat Immunol
; 20(11): 1409-1413, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562490
4.
Emerging opportunities for C3 inhibition in the eye.
Semin Immunol
; 59: 101633, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35787973
5.
C3-targeted host-modulation approaches to oral inflammatory conditions.
Semin Immunol
; 59: 101608, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35691883
6.
Complement C3 activation in the ICU: Disease and therapy as Bonnie and Clyde.
Semin Immunol
; 60: 101640, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35853795
7.
The Complement-Targeted Inhibitor Mini-FH Protects against Experimental Periodontitis via Both C3-Dependent and C3-Independent Mechanisms.
J Immunol
; 211(3): 453-461, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37306457
8.
Complement Is Required for Microbe-Driven Induction of Th17 and Periodontitis.
J Immunol
; 209(7): 1370-1378, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36028293
9.
From discovery to approval: A brief history of the compstatin family of complement C3 inhibitors.
Clin Immunol
; 235: 108785, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34147650
10.
Recent developments in C3-targeted complement therapeutics.
Semin Immunol
; 60: 101645, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35915008
11.
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.
Clin Immunol
; 215: 108450, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32360516
12.
Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates.
Clin Immunol
; 214: 108391, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32229292
13.
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Clin Immunol
; 220: 108598, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32961333
14.
Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery.
Trends Immunol
; 38(6): 383-394, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28416449
15.
Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.
Immunol Rev
; 274(1): 33-58, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27782325
16.
Taming hemodialysis-induced inflammation: Are complement C3 inhibitors a viable option?
Clin Immunol
; 198: 102-105, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30472267
17.
Safety profile after prolonged C3 inhibition.
Clin Immunol
; 197: 96-106, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30217791
18.
Attenuation of Staphylococcus aureus-Induced Bacteremia by Human Mini-Antibodies Targeting the Complement Inhibitory Protein Efb.
J Immunol
; 195(8): 3946-58, 2015 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26342032
19.
Complement-triggered pathways orchestrate regenerative responses throughout phylogenesis.
Semin Immunol
; 25(1): 29-38, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23684626
20.
Response to "Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19".
Clin Immunol
; 222: 108617, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33115645